ArticleWorld journal of gastroenterology2002
Metallothionein expression in hepatocellular carcinoma.
Article in World journal of gastroenterology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Pooled it
- Fusion transcripts landscape in hepatocellular carcinoma and potential impact on the expression of fusion partners.RNA biology · 2025Article
- Review
- Deriving time-concordant event cascades from gene expression data: A case study for Drug-Induced Liver Injury (DILI).PLoS computational biology · 2022Article
- ZNF479 downregulates metallothionein-1 expression by regulating ASH2L and DNMT1 in hepatocellular carcinoma.Cell death & disease · 2019Article
- Metallothionein gene expression in renal cell carcinoma.Indian journal of urology : IJU : journal of the Urological Society of India · 2014Article
- MT1M and MT1G promoter methylation as biomarkers for hepatocellular carcinoma.World journal of gastroenterology · 2014Article
- Zinc chelation: a metallothionein 2A's mechanism of action involved in osteosarcoma cell death and chemotherapy resistance.Cell death & disease · 2013Article
- MicroRNA-140 acts as a liver tumor suppressor by controlling NF-κB activity by directly targeting DNA methyltransferase 1 (Dnmt1) expression.Hepatology (Baltimore, Md.) · 2013Article
- Impact of delay to cryopreservation on RNA integrity and genome-wide expression profiles in resected tumor samples.PloS one · 2013Article
- Diurnal-and sex-related difference of metallothionein expression in mice.Journal of circadian rhythms · 2012Article
- Expression of claudin 10 protein in hepatocellular carcinoma: impact on survival.Journal of cancer research and clinical oncology · 2011Article
- Loss of metallothionein predisposes mice to diethylnitrosamine-induced hepatocarcinogenesis by activating NF-kappaB target genes.Cancer research · 2010Article
- Endocan expression correlated with poor survival in human hepatocellular carcinoma.Digestive diseases and sciences · 2009Article
- Acanthus ilicifolius plant extract prevents DNA alterations in a transplantable Ehrlich ascites carcinoma-bearing murine model.World journal of gastroenterology · 2007Article
- The complex functions of mast cells in chronic human liver diseases.Digestive diseases and sciences · 2006Review
- Gene expression profiles of hepatic cell-type specific marker genes in progression of liver fibrosis.World journal of gastroenterology · 2006Article
- Chemopreventive effect of vanadium in a rodent model of chemical hepatocarcinogenesis: reflections in oxidative DNA damage, energy-dispersive X-ray fluorescence profile and metallothionein expression.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2006Article
- Expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor in hepatocellular carcinoma: Impact on neovascularization and survival.World journal of gastroenterology · 2005Article
- Effects of PI3K and p42/p44 MAPK on overexpression of vascular endothelial growth factor in hepatocellular carcinoma.World journal of gastroenterology · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo investigate the expression of metallothioneins (MTs), which were recently thought to have close relationship with tumors, in human hepatocellular carcinoma.
methodsHistological specimens of 35 cases of primary human hepatocellular carcinoma with para-neoplastic liver tissue and 5 cases of normal liver were stained for MTs with monoclonal mouse anti-MTs serum (E9) by the immunohistochemical ABC technique.
resultsMTs were stained in the 35 cases of HCC, including 6 cases negative (17.1 %), 23 weakly positive (65.7 %), and 6 strongly positive(17.1 %). But MTs were stained strongly positive in all the five cases of normal liver and 35 cases of para-neoplastic liver tissue. The differences of MTs expression between HCC and normal liver tissue or para-neoplastic liver tissue were highly significant (P<0.01). The rate of MTs expression in HCC grade I was 100 percent, higher than that in grade II(81 %) and grade III and IV (78 %). But the differences were not significant (P>0.05). No obvious correlations between MTs expression in HCC and tumor size, clinical stage or serum alpha fetoprotein concentration were found (P>0.05).
conclusionDecrease of MTs expression in HCC may play a role in carcinogenesis of HCC. MTs are stained heterogenously in HCC. We can choose the anticancer agents according to the MTs concentration in HCC, which may improve the results of chemotherapy for HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.